Skip to main content
. 2021 Nov 13;12(11):1079. doi: 10.1038/s41419-021-04367-3

Fig. 1. Cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells.

Fig. 1

A HCT116 and DLD-1 cells were treated with RSL3 (1 μM), cetuximab (100 μg/ml) or their combination for 24 h. The inhibitory effects were determined by the CCK-8 assay. B Cell morphology changes were observed by inverted light microscopy. Scale bar, 100 μm. C The colony formation with the indicated treatment was performed (left panel), and a histogram of colony numbers is shown (right panel). **P < 0.01.